@prefix go: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 belv:translocationFrom go:0005622; belv:translocationOf sub:_2; belv:translocationTo go:0009986 . sub:_2 geneProductOf: hgnc:1338; a Protein: . sub:_3 occursIn: obo:CLO_0001925, species:9606; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject schem:Tetradecanoylphorbol%20acetate; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:\"Tetradecanoylphorbol acetate\") -> surf(p(HGNC:C5AR1))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "BEAS-2B cells pretreated with phorbol myristate acetate (200 ng/ml), a direct activator of PKC, had a similar binding profile to that seen in CSE-treated cells. Both treatments resulted in enhanced C5aR expression"; prov:wasQuotedFrom pubmed:15843499 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:15843499; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:32:43.413+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }